A multicenter, open-label, domestic phase II clinical trial to evaluate the diagnostic performance of 64Cu-PSMA-I&T PET/CT in patients with newly diagnosed prostate cancer scheduled for radical prostatectomy with pelvic lymphadenectomy
Latest Information Update: 14 Nov 2025
At a glance
- Drugs Cu 64 PSMA I and T Curium Pharma (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Sponsors PDRadiopharma
Most Recent Events
- 15 Oct 2025 According to PeptiDream media release, first patient enrolled in this trial
- 15 Oct 2025 Status changed from planning to recruiting as per PeptiDream media release
- 06 Oct 2025 New trial record